Log in | Register

“Salvage treatment” for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal

Garyfallia Poulakou| Dimitrios K. Matthaiou| Matteo Bassetti| Hakan Erdem| George Dimopoulos| Daniel J. Curcio| Jean Carlet| Jeffrey Lipman| Jean-François Timsit| Helen Giamarellou| Angelos Arfaras-Melainis| Jordi Rello
Letter
Volume 43, Issue 8 / August , 2017

Pages 1164 - 1166

No abstract available.

References

  1. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F et al (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776–795
  2. Wertheim H, Van Nguyen K, Hara GL, Gelband H, Laxminarayan R, Mouton J et al (2013) Global survey of polymyxin use: a call for international guidelines. J Glob Antimicrob Resist 1:131–134
    • View reference on publisher's website
    • View reference on PubMed
  3. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP et al (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284–3294
    • View reference on publisher's website
    • View reference on PubMed
  4. Polymyxin Article-31 referral—annex II. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Polymyxin-containing_medicines/human_referral_000383.jsp&mid=WC0b01ac05805c516f. Assessed Jan 2017
  5. Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL et al (2016) Updated United States and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 62:552–558
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement